Earnings digests and industry comparisons for Japan's biggest listed companies.
16 reports(page 1 of 2)
IDOM reported record-breaking sales growth in its fiscal first half ending February 2027, driven by robust infrastructure software demand. However, rising labor and outsourcing costs are beginning to cap net income gains.
Q2 (Oct-Dec) FY2026
Iwatani reported a stellar first quarter for FY2027, with net profit surging 569.6% to ¥31.72 billion, driven by soaring LPG prices and a large equity gain from Cosmo Energy Holdings. Revenue rose 13.1% to ¥233.36 billion, and operating profit more than doubled to ¥13.41 billion, hitting record highs across all profit metrics.
FY2027 Q1 (Apr–Jun 2026)
Sangetsu reported a 9.2% increase in first-quarter FY2027 revenue to ¥53.9 billion, with operating profit climbing 34.4% to ¥5.3 billion and net income soaring 71.6% to ¥4.8 billion, driven by strong domestic interior demand and pre-price hike buying. The results marked a record first-quarter profit for the company.
FY2027 Q1 (Apr-Jun 2026)
Daiwabo reported Q1 FY2027 results with revenue rising 7.8% to ¥313,148 million, while operating profit slumped 22.0% to ¥7,701 million, as a reversal of special PC demand and rising procurement costs weighed on earnings. Net income fell 19.5% to ¥5,795 million. The company kept its full-year guidance for a double-digit revenue and profit decline unchanged.
Q1 FY2027 (Apr-Jun 2026)
Inabata's Q1 FY2027 revenue rose 19.4% to ¥243,655 million, with operating profit surging 48.8% to ¥9,835 million, driven by gains across all segments and higher raw material prices amid Middle East tensions. Net income grew a more modest 5.6% to ¥6,376 million, reflecting the absence of a prior-year securities gain.
Q1 FY2027 (Apr-Jun 2026)
Medipal reported Q1 FY2027 revenue of ¥989,503 million, up 4.7% year on year, while operating profit fell 4.7% to ¥13,386 million, as margin erosion in the cosmetics and consumer goods unit outweighed gains in pharmaceutical wholesaling. Net profit surged 42.3% to ¥13,646 million, propelled by a ¥6,061 million gain on the sale of investment securities.
FY2027 Q1 (Apr-Jun 2026)
Misumi reported Q1 FY2027 revenue of ¥131.44 billion, up 32.3% year-on-year, as operating profit jumped 85.3% to ¥17.84 billion, prompting the company to lift full-year forecasts. The growth was driven by surging demand from data centers and semiconductor makers amid AI expansion, alongside the rollout of its digital model services like Fictiv and meviy, plus an automotive recovery.
Q1 FY2027 (Apr-Jun 2026)
IDOM revised its full-year consolidated net profit forecast down by approximately 26% to 10.5 billion yen for the fiscal year ending February 2027. The company is prioritizing aggressive capital investment in large stores and digital transformation (DX) initiatives to drive long-term value despite near-term margin pressure.
Daiwabo completed its treasury stock acquisition program, achieving a de facto full execution of the 6 billion yen cap. The company bought 1.69 million shares worth 5.9997 billion yen, signaling strong capital efficiency goals to investors.
Misumi announced plans to establish KIBAN, LLC in the US with a 40 million dollar investment to strengthen its global supply chain for the AI era. This move aims to secure mass production capabilities and accelerate growth through high-value localized manufacturing.
Misumi Group has resolved to establish a $50 million corporate venture capital fund in the United States, with plans to invest in robotics and industrial AI startups. The initiative aims to accelerate growth in the American market and build new revenue streams for next-generation manufacturing.
Hanwa will cancel 10.33 million treasury shares, reducing its total issued shares by 4.9 percent. This capital policy aims to boost earnings per share and enhance shareholder value through significant equity reduction.
